FindTrial
Sign In

Impact of dexamethasone on quality of recovery in patients undergoing surgery for gastrointestinal and hepato-pancreato-biliary malignancy- Randomized controlled trial

Impact of preoperative dexamethasone versus placebo on quality of recovery in patients undergoing surgery for gastrointestinal and hepato-pancreato-biliary malignancy- Randomized controlled trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093867
Enrollment
40
Registered
2025-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C159- Malignant neoplasm of esophagus, unspecified Health Condition 2: C169- Malignant neoplasm of stomach, unspecified Health Condition 3: C179- Malignant neoplasm of small intestine, unspecified Health Condition 4: C189- Malignant neoplasm of colon, unspecified Health Condition 5: C19- Malignant neoplasm of rectosigmoidjunction Health Condition 6: C20- Malignant neoplasm of rectum Health Condition 7: C210- Malignant neoplasm of anus, unspecified Health Condition 8: C229- Ma

Interventions

Intervention1: INJECTION DEXAMETHASONE: patient will be given one time - 8mg dexamethasone via intravenous route diluted in 100ml normal saline induction of anesthesia and before the start of surger

Sponsors

Aiims Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ? Patients undergoing curative intent elective surgery for gastrointestinal malignancy ? ECOG 0-2 ? Written, informed consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To evaluate the impact of preoperative dexamethasone on quality of recovery in patients undergoing surgery for GI and HPB malignancy (using QOR-40 score)Timepoint: post operative day 3 post operative day 5—

Secondary

MeasureTime frame
length of Intensive care Unit stayTimepoint: ;30 day morbidityTimepoint: 30 days—

Countries

India

Contacts

Public ContactShubham Agarwal

AIIMS Rishikesh

lokesharora1@gmail.com8564849303

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026